"10.1371_journal.pone.0128986","plos one","2015-06-08T00:00:00Z","Richat Abbas; Glen Park; Bharat Damle; Raul Chertkoff; Sari Alon","Pfizer, New York, NY, United States of America; Target Health, New York, NY, United States of America; Protalix Biotherapeutics, Carmiel, Israel","Conceived and designed the experiments: RC. Analyzed the data: RA GP RC SA. Contributed reagents/materials/analysis tools: RC SA. Wrote the paper: RA GP BD RC SA. Contributed interpretation of the data: BD. Contributed to the drafting of the article and approved the final version of the manuscript to be submitted for publication: RA GP BD RC SA.","Richat Abbas and Bharat Damle are employees of Pfizer, Sari Alon and Raul Chertkoff are employees of Protalix BioTherapeutics and Glen Park is an employee of Target Health, which provides clinical research services to Pfizer (http://www.pfizer.com) and Protalix BioTherapeutics (www.protalix.com). Pfizer and Protalix entered into an agreement in November 2009 to develop and commercialize taliglucerase alfa. This does not alter the authors adherence to the PLOS ONE policies on sharing data and materials.","2015","06","Richat Abbas","RA",5,TRUE,1,NA,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
